[Specialized ambulatory palliative care for urological tumors].

IF 0.4 4区 医学 Q4 UROLOGY & NEPHROLOGY Urologie Pub Date : 2025-08-01 Epub Date: 2025-04-04 DOI:10.1007/s00120-025-02573-x
Stephan Degener, Nici Markus Dreger, Friedrich-Carl von Rundstedt, Marie-Therese Schmitz, Ulrich Grabenhorst, Oliver Schmalz, Klaus Weckbecker, Johannes Just
{"title":"[Specialized ambulatory palliative care for urological tumors].","authors":"Stephan Degener, Nici Markus Dreger, Friedrich-Carl von Rundstedt, Marie-Therese Schmitz, Ulrich Grabenhorst, Oliver Schmalz, Klaus Weckbecker, Johannes Just","doi":"10.1007/s00120-025-02573-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Urologic tumors comprise about 20% of cancer diagnoses in Germany. To date, there are no studies with large datasets on the palliative situation of patients with urological tumors in the home environment, although dignified end-of-life care in the home environment is the wish of most cancer patients.</p><p><strong>Methods: </strong>Data from 5125 patients who received specialized outpatient palliative care (SAPV) with an underlying urological cancer between 2017 and 2021 were included in the analysis.</p><p><strong>Result: </strong>The analysis showed that 91.5% of patients died at home and the symptom burden remained stable or decreased slightly during treatment. The median survival time of patients receiving SAPV was 24 days. Factors such as age, performance status, loss of appetite, weakness, and pain at the start of treatment influenced the survival time of the patients. Relatives were largely very satisfied with the care provided.</p><p><strong>Conclusion: </strong>The study provides important insights into the palliative care of patients with urological tumors and underlines the importance of SAPV for dignified end-of-life care.</p>","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"784-792"},"PeriodicalIF":0.4000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12618423/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00120-025-02573-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/4 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Urologic tumors comprise about 20% of cancer diagnoses in Germany. To date, there are no studies with large datasets on the palliative situation of patients with urological tumors in the home environment, although dignified end-of-life care in the home environment is the wish of most cancer patients.

Methods: Data from 5125 patients who received specialized outpatient palliative care (SAPV) with an underlying urological cancer between 2017 and 2021 were included in the analysis.

Result: The analysis showed that 91.5% of patients died at home and the symptom burden remained stable or decreased slightly during treatment. The median survival time of patients receiving SAPV was 24 days. Factors such as age, performance status, loss of appetite, weakness, and pain at the start of treatment influenced the survival time of the patients. Relatives were largely very satisfied with the care provided.

Conclusion: The study provides important insights into the palliative care of patients with urological tumors and underlines the importance of SAPV for dignified end-of-life care.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
泌尿系统肿瘤的专科门诊姑息治疗。
背景:在德国,泌尿系统肿瘤约占癌症诊断的20%。尽管在家庭环境中有尊严的临终关怀是大多数癌症患者的愿望,但迄今为止,还没有关于泌尿系统肿瘤患者在家庭环境中姑息治疗情况的大数据集的研究。方法:2017年至2021年期间,5125名接受专科门诊姑息治疗(SAPV)的泌尿外科潜在癌症患者的数据被纳入分析。结果:91.5%的患者在家中死亡,治疗期间症状负担保持稳定或略有下降。接受SAPV治疗的患者中位生存时间为24天。治疗开始时年龄、运动状态、食欲不振、虚弱、疼痛等因素影响患者的生存时间。亲属们基本上对所提供的照顾非常满意。结论:本研究为泌尿系统肿瘤患者的姑息治疗提供了重要的见解,并强调了SAPV对有尊严的临终关怀的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Urologie
Urologie UROLOGY & NEPHROLOGY-
CiteScore
1.00
自引率
0.00%
发文量
0
期刊最新文献
[Treatment options in rare urological tumors: potential of molecular tumor boards]. [Drug interactions in uro-oncology]. [Charité survey: "Why did you come to the emergency room?"] [Poly (ADP-ribose) polymerase inhibitor combination therapy in metastatic castration-resistant prostate cancer]. [Urine cytology clearly recommended in the S3 guideline on the primary diagnosis of urothelial carcinoma].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1